Oncocross Co., Ltd. (KOSDAQ:382150)
South Korea · Delayed Price · Currency is KRW 3,030.00
-115.00 (-3.66%)
Oct 29, 2026, 3:30 PM KST
Oncocross Revenue
Oncocross had revenue of 58.12M KRW in the quarter ending June 30, 2026, a decrease of -57.81%. This brings the company's total for the last twelve months to 395.50M, down -61.91% year-over-year. In the year 2025, Oncocross had annual revenue of 370.46M, down -65.45%. That makes Oncocross the 45,074th largest company in the world by revenue and 2,601st in South Korea.
Revenue (ttm)
395.50M
Revenue Growth
-61.91%
P/S Ratio
99.95
Revenue / Employee
10.99M
Employees
36
Market Cap
39.53B
Revenue by Geography
- South Korea 1.01B 94.4%
- Overseas 59.54M 5.6%
Fiscal year ended Dec 31, 2024 See the full Oncocross breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 370.46M | -701.74M | -65.45% |
| Dec 31, 2024 | 1.07B | 980.68M | 1,071.49% |
| Dec 31, 2023 | 91.52M | -58.72M | -39.08% |
| Dec 31, 2022 | 150.25M | 50.25M | 50.25% |
| Dec 31, 2021 | 100.00M | 10.00M | 11.11% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| DongKook Pharmaceutical | 979.60B |
| Huons Global | 846.78B |
| PharmaResearch | 603.58B |
| KOLMAR BNH | 538.18B |
| ST Pharm | 386.46B |
| Sam Chun Dang Pharm. | 259.90B |
| BINEX | 157.28B |
| Oscotec | 144.18B |